Previous 10 | Next 10 |
AAIC, ACB, ACHV, AFRM, AGRO, AGRX, APDN, APTX, AQN, AVPT, AXU, BANX, BBI, BEAT, BIOL, BLBD, BLND, BOXL, BSQR, CBAY, CDXC, CLLS, CLVR, CODX, COMP, CORZ, CRMD, CTIC, CURI, CWCO, DARE, DUOL, EDR, ETON, EYEN, FIGS, GPL, GWH, HLI, HTGM, IBIO, IDN, OTCQB:IGXT, IMMR, INDI, INTZ, INUV, JOBY, KMPH, LC...
VANCOUVER and MINNEAPOLIS - ( NewMediaWire ) - April 29, 2022 - Neovasc Inc. ( NASDAQ , TSX : NVCN), will report financial results for the quarter ended March 31, 2022 on Thursday, May 12, 2022. Neovasc’s President and Chief Executive Officer Fred Colen, and Chri...
Report demonstrates objective improvements in patients suffering from microvascular dysfunction VANCOUVER and MINNEAPOLIS - ( NewMediaWire ) - April 28, 2022 - Neovasc , Inc. ("Neovasc" or the "Company") ( NASDAQ , TSX : NVCN) today announced that the European Heart...
VANCOUVER and MINNEAPOLIS - ( NewMediaWire ) - April 20, 2022 - Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the 2022 Bloom Burton & Co. Healthcare Investment Conferen...
VANCOUVER, BC - ( NewMediaWire ) - April 13, 2022 - Neovasc Inc. (“ Neovasc ” or the “ Company ”) (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders held on April ...
VANCOUVER - ( NewMediaWire ) - March 24, 2022 - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, and in the development of minimally invasive transcatheter mitral valve replac...
Neovasc Inc. (NVCN) Q4 2021 Earnings Conference Call March 10, 2022, 04:30 PM ET Company Participants Mike Cavanaugh - MD, Westwicke Fred Colen - President and Chief Executive Officer Chris Clark - Chief Financial Officer Conference Call Participants Vernon Bernardino - H.C. Wainwright & ...
Neovasc press release (NASDAQ:NVCN): Q4 GAAP EPS of -$0.40 misses by $0.30. Revenue of $2.54M (+29.6% Y/Y) beats by $1.74M. For further details see: Neovasc GAAP EPS of -$0.40 misses by $0.30, revenue of $2.54M beats by $1.74M
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - March 10, 2022) - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2021. Highlights Achieved record revenue in Q4 o...
Vancouver, British Columbia--(Newsfile Corp. - February 24, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the quarter and full year ended December 31, 2021 on Thursday, March 10, 2022. Neovasc's President and Chief Executive Officer Fred Colen, a...
News, Short Squeeze, Breakout and More Instantly...
Neovasc Inc. (NASDAQ: NVCN) is the focus of IBN's latest stock spotlight. The company's shares have moved -1.48% on the day to $29.23. Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. It...
VANCOUVER and MINNEAPOLIS, MN, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2022. Recent Hi...
VANCOUVER, BC, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as d...